scholarly journals Serum HDL Cholesterol Measurement

2020 ◽  
Author(s):  
1988 ◽  
Vol 34 (8) ◽  
pp. 1629-1632 ◽  
Author(s):  
T A McMillan ◽  
G R Warnick

Abstract We conducted a proficiency survey of cholesterol and high-density lipoprotein (HDL) cholesterol analysis in local clinical laboratories to determine whether increased national emphasis on cholesterol measurement had resulted in changes in performance from previous surveys. Sets of frozen aliquots of plasma and HDL supernate pools were sent to nine laboratories for analysis; results were compared with Northwest Lipid Research Center values, and relationships were determined by linear regression. Of all the cholesterol measurements, 81% were considered acceptable (i.e., within 9% of the NWLRC value), and 61% of the HDL cholesterol measurements were considered acceptable (within 50 mg/L of NWLRC values). These data represented no improvement over previous surveys. Workload had increased significantly: 79% for cholesterol and 284% for HDL cholesterol. On a bias plot, six of the laboratories demonstrated inaccuracy greater than the +/- 3% recommendation within the critical range of 2000-2400 mg/L for total cholesterol. For HDL cholesterol, two laboratories demonstrated bias greater than 10% at the critical point of 350 mg/L, with three additional laboratories displaying strong bias outside the decision point. The survey results indicate that apparently further improvements must be made for laboratories to achieve acceptable performance in cholesterol analysis.


1983 ◽  
Vol 29 (3) ◽  
pp. 516-519 ◽  
Author(s):  
G R Warnick ◽  
J M Benderson ◽  
J J Albers

Abstract Proficiency surveys of Seattle-area laboratories suggest only slight improvement in overall performance in high-density lipoprotein (HDL) measurement between 1978 and 1982, although the reported workload for HDL has increased by 15%. The mean interlaboratory SD was 64 mg/L (ranging from 34 for a pool averaging 299 mg/L to 136 for a pool averaging 886 mg of HDL cholesterol per liter) in 1982, compared with 79 mg/L (range 48-155) in 1978-79. Of the individual laboratory results in the current survey, 39% deviated by more than 50 mg/L from target values as compared with 37% in 1978-79. The discrepant values were primarily ascribable to method inaccuracy: only 30% of laboratories in 1982 reported results that averaged within 30 mg/L of target values (vs 50% in 1978). For within-run precision, 80% of laboratories in 1982 had SDs of less than 30 mg/L, vs 70% in 1978. The 1982 survey included a lyophilized serum prepared by spray freezing and bulk lyophilization (Hyland Omega), identical to the pools used in the College of American Pathologists Comprehensive Chemistry Survey, and five pools of frozen plasma. Interlaboratory variation and biases for the Omega pool were similar to those for the frozen pools.


1992 ◽  
Vol 38 (8) ◽  
pp. 1437-1439
Author(s):  
R W Hardy ◽  
R H Ng ◽  
R E Hill ◽  
S Walker ◽  
K M Sparks ◽  
...  

Abstract We evaluated the Clinistat Analyzer (Miles Inc., Diagnostics Division, Elkhart, IN) for measuring cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol at three medical centers. The system, based on multilayer film technology, uses precalibrated, dry film reagent disks. Ten microliters of serum is applied to the dry film reagent disk in the test procedure. For HDL-cholesterol measurement, serum is pretreated by precipitation with phosphotungstic acid and magnesium chloride. Total precision (CVs) of each of the three assays was less than or equal to 5%. The assay ranges were linear and satisfactory for clinical use. Patients' results compared well with established methods. No significant interferences were found with hemolysis, icterus, and lipemia.


VASA ◽  
2005 ◽  
Vol 34 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Brunner-La Rocca ◽  
Schindler ◽  
Schlumpf ◽  
Saller ◽  
Suter

Background: Previous studies showed an anti-atherosclerotic effect of PADMA 28, an herbal formula based on Tibetan medicine. As the mechanisms of action are not fully understood, we investigated whether PADMA 28 may lower blood lipids and lipid oxidisability, and affect early endothelial dysfunction. Patients and methods: Sixty otherwise healthy subjects with total cholesterol ≥5.2 mmol/l and < 8.0 mmol/l were randomly assigned to placebo or PADMA 28, 3 x 2 capsules daily, for 4 weeks (double-blind). Blood lipids (total, LDL-, and HDL-cholesterol, triglycerides, Apo-lipoprotein A1 and B) and ex vivo lipid oxidisability were measured before and after treatment. In a subset of 24 subjects, endothelial function was assessed using venous occlusion plethysmography with intraarterial infusion of acetylcholine. Isolated LDL and plasma both untreated and pre-treated with PADMA 28 extract were oxidised by the radical generator AAPH. Conjugated diene formation was measured at 245 nm. Results: Blood lipids did not change during the study in both groups. In contrast to previous reports in mild hypercholesterolaemia, no endothelial dysfunction was seen and, consequently, was not influenced by therapy. Ex vivo blood lipid oxidisability was significantly reduced with PADMA 28 (area under curve: 5.29 ± 1.62 to 4.99 ± 1.46, p = 0.01), and remained unchanged in the placebo group (5.33 ± 1.88 to 5.18 ± 1.78, p > 0.1). This effect persisted one week after cessation of medication. In vitro experiments confirmed the prevention of lipid peroxidation in the presence of PADMA 28 extracts. Persistent protection was also seen for LDL isolated from PADMA 28-pretreated blood after being subjected to rigorous purification. Conclusions: This study suggests that the inhibition of blood lipid oxidisability by PADMA 28 may play a role in its anti-atherosclerotic effect.


1989 ◽  
Vol 62 (02) ◽  
pp. 797-801 ◽  
Author(s):  
E Berg Schmidt ◽  
E Ernst ◽  
K Varming ◽  
J O Pedersen ◽  
J Dyerberg

SummaryPlasma lipids and haemostasis were investigated in 17 patients with hyperlipidaemia before and after 6 weeks supplementation with 6 g n-3 fatty acids. Nine of the patients had type IIa and 8 had type IV hyperlipidaemia. No effect on plasma cholesterol, LDL- or HDL-cholesterol were seen, but plasma triglycerides decreased after n-3 supplementation. Apolipoprotein B increased and apolipoprotein A1 decreased after the oil supplement. The bleeding time was prolonged, but platelet aggregation was unaltered by n-3 fatty acids. Protein C activity increased in type II a and decreased in type IV after the supplement. Fibrinolysis was markedly depressed while von Willebrand factor antigen was reduced after intake of n-3 fatty acids.


1986 ◽  
Vol 55 (02) ◽  
pp. 173-177 ◽  
Author(s):  
K Desai ◽  
J S Owen ◽  
D T Wilson ◽  
R A Hutton

SummaryPlatelet aggregation, platelet lipid composition and plasma lipoprotein concentrations were measured each week in a group of seventeen alcoholics, without overt liver disease, for one month, following acute, total alcohol withdrawal. The platelets were initially hypoaggregable but, within 1-2 weeks of cessation of drinking, they became hyperaggregable and then gradually returned towards normal values. Hyperaggregability could not be explained by increases in either the cholesterol or the arachidonic acid content of the platelets. Plasma very-low-density lipoprotein cholesterol levels remained high throughout the study, but the initially raised levels of high-density lipoprotein (HDL) cholesterol fell by 26%. Low-density lipoprotein (LDL) cholesterol concentration rose by 10% after two weeks of withdrawal but then returned to about the starting level. The resulting changes in the plasma LDL-cholesterol: HDL-cholesterol ratio, which had increased by more than 50% after two weeks of abstinence, essentially paralleled the time course of enhanced platelet reactivity in all but four of the alcoholics. These findings suggest that alterations in plasma lipoprotein concentrations during acute alcohol withdrawal may be a contributory factor to the haemostatic disorders present in such patients.


2014 ◽  
Author(s):  
You-Cheol Hwang ◽  
In-Kyung Jeong ◽  
Kyu Jeung Ahn ◽  
Ho Yeon Chung ◽  
Cheol-Young Park

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 38-LB
Author(s):  
UPENDRA KAUL ◽  
PEEYUSH JAIN ◽  
RANJAN KACHRU ◽  
VINEET BHATIA ◽  
PRIYADARSHINI ARAMBAM ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document